anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
One of the growing challenges to public health and clinical outcomes is the emergence of cognitive impairments, particularly depressive symptom severity, because of chronic elevations in metabolic disease and cerebrovascular disease risk. To more clearly delineate these relationships and to assess the potential for sexual dimorphism, we used lean (LZR) and obese Zucker rats (OZR) of increasing age to determine relationships between internal carotid artery (ICA) hemodynamics, cerebral vasculopathies, and the emergence of depressive symptoms. Male OZR exhibited progressive elevations in perfusion pressure within the ICA, which were paralleled by endothelial dysfunction, increased cerebral arterial myogenic activation, and reduced cerebral cortex microvessel density. In contrast, female OZR exhibited a greater degree of ICA hypertension than male OZR but maintained normal endothelial function, myogenic activation, and microvessel density to an older age range than did males. Although both male and female OZR exhibited significant and progressive elevations in depressive symptom severity, these were significantly worse in females. Finally, plasma cortisol concentration was elevated higher and at a younger age in female OZR as compared with males, and this difference was maintained to final animal usage at ∼17 wk of age. These results suggest that an increased severity of blood pressure waves may penetrate the cerebral circulation more deeply in female OZR than in males, which may predispose the females to a more severe emergence of depressive symptoms with chronic metabolic disease, whereas males may be more predisposed to more direct cerebral vasculopathies (e.g., stroke, transient ischemic attack).NEW & NOTEWORTHY We provide novel insight that the superior maintenance of cerebrovascular endothelial function in female versus male rats with chronic metabolic disease buffers myogenic activation of cerebral resistance arteries/arterioles despite worsening hypertension. As hypertension development is earlier and more severe in females, potentially due to an elevated stress response, the blunted myogenic activation allows greater arterial pressure wave penetrance into the cerebral microcirculation and is associated with accelerated emergence/severity of depressive symptoms in obese female rats.
The invention discloses a smoking stopping medicine, belonging to the medical technical field, in particular to a smoking stopping medicine by means of traditional Chinese medicine. The medicine consists of the following parts by weight of components: 10-25 portions of panacis quinquefolii radix, amoorcorn tree bark, Atractylodes macrocephala respectively, 10-20 portions of Chinese angelica, 5-15 portions of pericarpium citri reticulatae, 15-25 portions of liquorice, 5-15 portions of rhizoma gastrodiae, 10-25 portions of fritillaria roylei hooker and 10-25 portions of radix astragali. By using the illness field caused by a plurality of factors in pathological changes of human body, that is, simulation acupuncture and moxibustion of low-frequency electronic pulse therapeutic apparatus, infrared ray heating and field effect magneto-therapy, a substance of 'opium peptide' can be reproduced by human brain, which can restrain and remove the addiction of the human body to nicotine and craving for tobacco. The smoking stopping liquid of the invention is spread on the acupuncture points of smoking stopping. then the electrodes of the low-frequency electronic pulse therapeutic apparatus is arranged on the acupuncture points coated with smoking stopping liquid and the power is switched on to lead in the smoking stopping liquid. By doing twice a day for successive two to three days, the smoking addiction can be given up. The invention has the advantages of low price, prominent effect, short duration and free from rebouncing.
Venetoclax (VEN) in combination with hypomethylating agents (HMAs) is considered the standard of treatment for individuals with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy. We conducted a retrospective analysis that encompassed 16 critically ill patients newly diagnosed with AML who were admitted to the intensive care unit (ICU) and received the VEN and HMA regimen. Among them, 13 were primary AML, and three were MDS-transformed AML. The mean Acute Physiology and Chronic Health Evaluation II (APACHE II) score was 18.9, and the mean sepsis-related organ failure assessment score (SOFA) was 6.2. The average length of the ICU stay was 27.3 days. The median duration of VEN administration was 16 days. After the first course of VEN + HMA, 12 cases (75%) achieved complete remission (CR) or CR with incomplete haematological recovery (CRi). Among the five patients harbouring TP53 mutations, the overall response rate (ORR) was 90%. All patients experienced grade 3-4 haematological adverse events (AEs). With a median follow-up of 9.5 months (range: 0.5-23), the overall survival (OS) rate was 43.75%. TP53-wild patients and CR state after the first course of VEN-HMA indicated better survival. The combination of VEN and HMA has demonstrated a significantly elevated therapeutic response rate in newly diagnosed AML patients with critical illness.
A pharmaceutical composition for use in relieving cold and cough symptoms in a mammal includes ibuprofen, hydrocodone bitartrate and an antihistamine (or a decongestant). The ibuprofen is in a therapeutically effective amount sufficient to act as an analgesic and an anti-inflammatory. The hydrocodone bitartrate is in a therapeutically effective amount sufficient to act as an antitussive and an analgesic. The antihistamine is in a therapeutically effective amount to act as an antihistamine. A fatty excipient may be added to the active ingredients to facilitate encapsulation. Multiple layers of the fatty excipient may be employed in varying release formulations and to facilitate identification of the composition.
Ischemic stroke is the leading cause of disability and mortality globally. Atrial fibrillation（AF） is a well-established risk factor for ischemic stroke and responsible for up to one-third of all strokes. AF-related ischemic strokes are more frequently fatal or disabling than non-AF strokes. The overall prevalence of known or newly diagnosed AF in stroke patients is approximately 39.0%. Detecting underlying AF remains important for secondary prevention of recurrent stroke, with a different strategy from atherosclerotic cause of stroke. The increasingly common use of prolonged cardiac monitoring (PCM) after ischemic stroke has greatly increased the detection rates of previously undiagnosed AF in ischemic strokes, which was demonstrated by a series of trials. Additionally, AF burden, defined as percentage of the time in AF during cardiac monitoring, has been regarded as an important prognostic risk factor for thromboembolism.

Currently, the CHA2DS2-VASc score is the most widely used scoring system for assessing ischemic stroke risk in patients with AF and basis for initiation of anticoagulation. Anticoagulation is currently recommended for male with CHA2DS2-VASc score≥2 or female with CHA2DS2-VASc score≥3. Direct oral anticoagulants (DOACs) have been increasingly used in the past decade due to their similar to superior efficacy to vitamin K antagonists (VKAs), but a lower intracerebral bleeding risk in non-valvular atrial fibrillation (NVAF), defined as AF in the absence of moderate to severe mitral stenosis or a mechanical heart valve. For patients with AF who cannot tolerate long-term OACs due to various relative or absolute contraindications, left atrial appendage closure (LAAC) offers an alternative treatment strategy for these patients. Moreover, as one-third of patients with ischemic stroke and AF may have concomitant large artery atherosclerosis or small vessel disease, it is still unclear whether these patients should be left untreated or treated with antiplatelet (APT), DOACs, or with LAAC.

Traditional clinical practice mainly focuses on the presence of AF but rarely incorporates AF burden into a risk stratification scoring system. To our knowledge, no studies to date have investigated recurrent stroke risk stratification in AIS patients with AF based on AF burden assessed by PCM, not to mention guidance of treatment strategy selection. Further, other multimodal assessments, such as cerebral CT/MRI (e.g. infarct size and location), serum biomarkers (e.g. BNP, troponin, D-dimer levels) and cardiac structural markers (e.g. LA volume or volume index, LAA morphologies) have been reported as promising prognostic factors of stroke severity and recurrence. A comprehensive evaluation system is still lacking. In this prospective and multicenter registry study, we determine to test the safety and effectiveness of best medical therapy (OAC, APT) and LAAC using multimodal assessment from combined brain and cardiologic work-up, with the aim to optimize secondary prevention in this patient population.
11.1. This blood bag system includes a 16 gauge × 1 1/2 inch (1.60 × 38 mm) needle with needle cover and a 500mL (nominal capacity 600mL) collection bag containing 70mL Citrate Phosphate Dextrose (CPD) anticoagulant. The Quadruple blood bag set has one integrally attached empty primary bag, one empty satellite bag, and one satellite bag containing 111 mL OPTISOL Red Cell Preservative Solution.

11.2. Blood bag codes ending in A2 are the collection set with an Integral Diversion Blood Sampling Arm for obtaining donor samples prior to collection of the Whole Blood Unit. 11.3. Blood bag codes ending in A2 also include a DonorCare® Needle Guard pre-attached to the donor tubing. DonorCare Needle Guard device instructions are provided on the reverse side.

11.4. The blood bag collection set is made of PVC (polyvinyl chloride with DEHP plasticizer).

11.5. The blood bag has no components made of natural rubber latex.

11.6. Tubing internal diameter (ID) nominal 3.0 mm.

11.7. Tubing outer diameter (OD) nominal 4.4 mm.

11.8. Tubing line maximum 16 segments available.
Participants received 140 mg evolocumab every 2 weeks (Q2W) administered by subcutaneous injection for 6 weeks during the primary period of the study. Starting at week 6 (beginning of the post-primary period), participants received 140 mg evolocumab Q2W up to week 24.
Example embodiments described herein relate to a closed-loop artificial pancreas system. The artificial pancreas system is intended to automatically and continuously control the blood glucose level of a user by simulating the endocrine function of a healthy pancreas. The artificial pancreas system uses a closed loop control system having a cost function. The penalty function helps to limit the infusion rate of insulin in an attempt to avoid hypoglycemia and hyperglycemia. However, unlike conventional systems that use general or baseline parameters for a user's insulin needs in a cost function, example embodiments may use custom parameters in the cost function that reflect the user's personalized insulin needs. Using custom parameters will cause the cost function to produce insulin doses over a period of time that are more suitable for the user's personalized insulin needs. This helps to better avoid hypoglycemia and hyperglycemia.
Isolated extracellular matrix-binding proteins, designated ClfB, SdrC, SdrD and SdrE, and their corresponding amino acid and nucleic acid sequences and motifs are described. The proteins, peptides, fragments thereof or antigenic portions thereof are useful for the prevention, inhibition, treatment and diagnosis of $i(S. aureus) infection and as scientific research tools. Further, antibodies or antibody fragments to the proteins, peptides, fragments thereof or antigenic portions thereof are also useful for the prevention, inhibition, treatment and diagnosis of $i(S. aureus) infection. In particular, the proteins or antibodies thereof may be administered to wounds or used to coat biomaterials to act as blocking agents to prevent or inhibit the binding of $i(aureus) to wounds or biomaterials. C1fB is a cell-wall associated protein having a predicted molecular weight of approximately 88 kDa and an apparent molecular weight of approximately 124 kDa, which binds both soluble and immobilized fibrinogen. C1fB binds both the alpha and beta chains of fibrinogen and acts as a clumping factor. SdrC, SdrD and SdrE are cell-wall associated proteins that exhibit cation-dependent ligand binding to the extracellular matrix. It has been discovered that in the A region of SdrC, SdrD, SdrE, C1fA and C1fB, there is a highly conserved amino acid sequence that can be used to derive a consensus motif of TYTFTDYVD.
The placebo will be given to the patient 2 a day for between 2-7 days preoperatively. Participation in this study requires 6 separate blood tests commencing at the start of surgery and continuing for 24 hours immediately post operatively.
An object of the present disclosure is to develop a new combined therapy that exhibits an excellent antitumor effect as compared with administration of an anti-CD26 antibody alone. In order to evaluate both a function of an immune checkpoint inhibitor and an antitumor effect of the anti-CD26 antibody, it is necessary to include both an immune system syngeneic with a cancer cell and a binding site on a human CD26 molecule. That is, in order to acquire data of the immune checkpoint inhibitor and the anti-CD26 antibody, analysis in a human tumor cell line and a human immune system is essential. Therefore, the present inventors tried to produce a human immunized mouse as a model animal for confirming a combined action of the anti-CD26 antibody and the ICI, and succeeded in producing a model mouse excellent in generation of human T cells. Subsequently, in a cancer-bearing model using this mouse, a combined effect of the anti-CD26 antibody and the immune checkpoint inhibitor was studied. As a result, it has been found that this combined drug has a stronger synergistic effect than each single drug.
979,184. Surgical dressings. A. CURTAY. April 7, 1961 [May 21, 1960], No. 12519/61. Heading A5R. A device for treatment of legs comprises an outer stocking of liquid-impervious plastic material and an inner stocking which is elastic and pervious to liquids and which is impregnated with a liquid. A stocking 2 or sock of absorbent elastic material, e.g. woven or knitted cotton, is impregnated with cream or lotion and is covered by an impermeable synthetic plastic or rubberized fabric sheath 3 which has an elastic band 4 at the top. The stocking or sock and the sheath may be joined.
Consumption of 282.81 ml of product 1 (corresponding to 25g of glucose). Subjects will take this amount only on the day of the visit that they are to consume this product.
This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF[alpha] antagonist. The NGF antagonist and the TNF[alpha] antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF[alpha] antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF[alpha] antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF[alpha] antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF[alpha] antagonist administered alone.
Interleukin-1 (IL-1) blockade may interfere with the immune response to infections. Treatment with another medication that works through inhibition of IL-1 has been associated with an increased risk of serious infections, and serious infections have been reported in patients taking ARCALYST [see Clinical Studies (14)]. There was a greater incidence of infections in CAPS and RP patients on ARCALYST compared with placebo.

In the controlled portion of the CAPS study [see Clinical Studies (14.1)], severe infection (bronchitis) was reported in one patient receiving ARCALYST. In an open-label extension study in CAPS, one patient developed bacterial meningitis and died [see Adverse Reactions (6.1)]. 

In clinical studies, ARCALYST has not been administered concomitantly with tumor necrosis factor (TNF) inhibitors. An increased incidence of serious infections has been associated with administration of an IL-1 blocker in combination with TNF inhibitors. ARCALYST is not recommended for use with TNF inhibitors because this may increase the risk of serious infections.

Drugs that affect the immune system by blocking TNF have been associated with an increased risk of reactivation of latent tuberculosis (TB). It is possible that taking drugs such as ARCALYST that block IL-1 increases the risk of TB or other atypical or opportunistic infections. Refer to current practice guidelines for evaluation and treatment of possible latent tuberculosis infections before initiating therapy with ARCALYST.

Treatment with ARCALYST should not be initiated in patients with an active or chronic infection. Discontinue ARCALYST if a patient develops a serious infection.
HIV infection is a widespread health problem in the U.S. Antiretroviral treatment has increased longevity and changed the nature of risk factors for morbidity and mortality. Alcohol consumption has become an increasingly serious health issue among HIV primary care patients. Drinking is a key factor in progression to severe liver damage (especially those co-infected with hepatitis), and liver disease is now one of the most common causes of death among those with HIV. Excess drinking is also associated with medication noncompliance, reduces the effect of antiretroviral treatment, and is linked to other health problems. Therefore, helping HIV patients reduce unsafe drinking is crucial to their long-term health. The intervention combines the brief MI, an established, evidence-based counseling approach, with an innovative procedure designed to strengthen the effects of the MI. An effective, easily implemented alcohol-reduction intervention could be incorporated into standard care in HIV clinics helping prevent or slow the progress of some medical problems in HIV-infected individuals, improve medication compliance, prolong lifespan and decrease risk behavior associated with alcohol use.

Comparison(s): Enhanced brief motivational interview (including an IVR component for alcohol self-monitoring purposes), brief motivational interview, viewing a DVD on HIV self-care.
Patients that are randomized to only usual care group will receive guideline-standardized medications and lifestyle recommendations. Cardiovascular risk management and compliance to medication and lifestyle recommendation will be assessed and controlled by three cardiologists in clinical visits performed at 6 and 12 months. For the necessary cases counseling to other specialities will be performed for smoke cessation and weight management.
Broad-spectrum antiviral traditional Chinese medicine monomer berbamine and application thereof. The invention discloses a broad-spectrum antiviral traditional Chinese medicine monomer which is berbamine. The invention also discloses a broad-spectrum antiviral drug composition which comprises berbamine or one or more pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier or diluent thereof. The invention also discloses the application of the broad-spectrum antiviral traditional Chinese medicine monomer or the broad-spectrum antiviral medicine composition in serving as a virus infection inhibitor and/or in preparing a medicine for preventing and treating virus infectious diseases. The invention provides a potential broad-spectrum antiviral drug for the prevention and treatment of various virus infectious diseases. The invention is the development of the clinical application of berbamine.
PURPOSE: A method for preparing a mesenchymal stem cell culture medium containing cell growth factor of high concentration is provided to remarkably enhance the content of the cell growth factor. CONSTITUTION: A method for preparing a mesenchymal stem cell culture medium comprises: a step of culturing the mesenchymal stem cells; a step of three-dimensionally culturing the mesenchymal stem cell with a biocompatible scaffold; and a step of collecting the culture medium. The mesenchymal stem cells are cultured by adding bFGF(basic fibroblast growth factor) or EGF(epidermal growth factor) in a serum-free medium. The biocompatible scaffold is a natural and synthetic polymer. A composition of mesenchymal stem cell culture medium contains a large amount of growth factors and cytokines. A therapeutic agent composition for wound healing contains the composition of mesenchymal stem cell culture medium. A cosmetic composition contains the composition of mesenchymal stem cell culture medium. [Reference numerals] (AA,DD,GG,JJ) 3 days; (BB,EE,HH,KK) 6 days; (CC,FF,II,LL) 9 days
BACKGROUND: Bicuspid aortic valve disease (BAV) is present in 0.5-2% of the population and can promote aortic dilation, eventually leading to fatal consequences. Although some biomarkers have been proposed in adults, no studies have tested these candidates in children. We aimed to evaluate four miRNAs previously described to be related to BAV disease and aortic dilation in adults in a paediatric cohort.
METHODS: Eighty participants ≤17 years old (4-17; mean 12) were included. From the BAV group, 40% had a dilated aorta (z score >2). RT‒qPCR were performed in plasma samples to quantify miR-122, miR-130a, miR-486, and miR-718 using the delta-delta Ct method. Functional and enrichment analyses of miR-130a were also performed.
RESULTS: miR-130a expression in plasma was found to be significantly lower in BAV patients with a dilated aorta versus nondilated patients (p = 0.008) and healthy TAV controls (p = 0.004). Furthermore, miR-130a expression in plasma was inversely correlated with ascending aorta (r = 0.318, p = 0.004) and aortic root z scores (r = 0.322; p = 0.004). Enrichment analysis showed that miR-130a target genes are related to the TGFβ signalling pathway.
CONCLUSIONS: miR-130a expression in plasma is decreased in aortic-dilated BAV children compared to nondilated BAV children, helping differentiate low- to high-risk patients.
IMPACT: miR-130a expression in plasma is related to aortic dilation in bicuspid aortic valve (BAV) children. To our knowledge, this is the first study that analyses miRNA patterns in bicuspid aortic valve children with aortic dilation. miR-130a expression in plasma could be a biomarker in order to help differentiate low-to high-risk BAV children, which is vitally important for advanced care planning.